Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

One Year After Spike In American Deaths From China-sourced Contaminated Heparin, U.S. Pharmocopeia Issues Revised Standards

This article was originally published in PharmAsia News

Executive Summary

BEIJING - When heparin sourced from China mysteriously and suddenly began triggering a spike in extreme adverse reactions and deaths across American hospitals 18 months ago, U.S. FDA rapidly called on the U.S. Pharmacopeial Convention to help devise new testing methods to determine the purity and quality of the blood thinner
Advertisement

Related Content

After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
FDA Identifies Excipients At Risk for Potential Melamine Contamination; Issues Alert That New USP Standards for Heparin Products Will Result in Decreased Potency
FDA Identifies Excipients At Risk for Potential Melamine Contamination; Issues Alert That New USP Standards for Heparin Products Will Result in Decreased Potency
U.S. Pharmacopeia Ramps Up Drug Quality, Safety Cooperation Across Asia With Four New Agreements With China, ASEAN States
FDA Sends Warning Letters To Two Chinese Producers Of Adulterated Heparin
FDA Sends Warning Letters To Two Chinese Producers Of Adulterated Heparin
Advertisement
UsernamePublicRestriction

Register

SC072691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel